Episode Details
Back to Episodes
Daily Roundup | EyePoint Crashes 67% After Duravyu Fails Phase 3 in Wet AMD
Published 1 month ago
Description
EyePoint stock crashed 67% after Duravyu missed its primary endpoint against aflibercept in the LUGANO Phase 3 for wet AMD - with nine vision-loss cases in the treatment arm versus zero. Also: argenx's Vyvgart Hytrulo hits in autoimmune myositis, AstraZeneca scraps its volrustomig bispecific in lung cancer while Enhertu and Tagrisso win, Sandoz signs a $322M biosimilar deal with Shanghai Henlius, Cytokinetics sues Bristol Myers Squibb over aficamten and Camzyos, and Slate Medicines merges with Fulcrum Therapeutics. Visit us at thepharmacloseout.com.